Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty

Phase 4

Completed

• Conditions: Pain, Postoperative; Ropivacaine; Therapeutic Use; Arthroplasty, Replacement, Hip
• Interventions: Drug: Ropivacaine; Drug: Saline

• Registration Number: NCT02344264
• Lead Sponsor: Daniel Hägi-Pedersen

Brief Summary

The patients will be included the 1. or 2. day after surgery. All THA patients will be screened. Those reporting VAS \> 40 during active 30 degrees hip flexion will be asked to participate.

Included patients will receive 2xNCFL (singleshot) first placebo (8 ml saline) and then ropivacaine (8 ml ropivacaine 7,5mg/ml) or the other way around (randomized). There will be 45 minutes between the two blockades. The blockades will be ultrasound guided.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01
• Study First Submitted: 2015-01-16
• Study First Submitted QC: 2015-01-16
• Study First Posted: 2015-01-22
• Status Verified: 2015-09
• Primary Completion: 2015-09
• Study Completion: 2015-09
• Last Update Submitted: 2015-09-24
• Last Update Posted: 2015-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• THA within 48 hours and VAS>40 during active 30 degrees hip flexion despite conventional pain medication.
• informed consent
• ASA 1-3
• BMI 18-40

Exclusion Criteria

• Unable to communicate in danish
• Allergic reactions toward drugs used
• Abuse of alcohol/drugs
• Unable to cooperate
• Pregnant women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
RP	Ropivacaine	first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
RP	Saline	first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
PR	Saline	first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
PR	Ropivacaine	first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml

Primary Outcome Measures

Name	Time	Method
Difference in VAS between NCFL and placebo during active 30 degrees hip flexion	45 min

Secondary Outcome Measures

Name	Time	Method
Difference in mean VAS between the groups during active hip flexion	15, 30, 45, 60, 75, 90 min
Difference in mean VAS between the groups at rest	15, 30, 45, 60, 75, 90 min

Trial Locations

Locations (1)

Department of Anaesthesiology; 🇩🇰 Næstved, Danmark, Denmark